Zimmer Biomet Buys LDR To Boost Spine Revenue Growth
Executive Summary
The world's second-largest orthopedic device firm, Zimmer Biomet, is making its biggest move since Zimmer and Biomet merged in 2015 with a $1 billion acquisition of spine-device specialists LDR.
You may also be interested in...
Zimmer Biomet Supply Woes Could Leave An Opening In Joint Markets
Zimmer Biomet said it was not able to maintain supply to meet strong demand for its hip, knee and other joint products that grew out of cross-selling opportunities. As a result, the firm fell short of financial expectations in Q3. The company said it is working to improve its supply-chain procedures, but there could be a short-term chance for competitors to make some gains, analysts suggest.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.